• Latest results from the Remplir Real World Evidence (RWE) study demonstrate an overall treatment success rate of 89.7%
• 90.3% of motor nerve repairs resulted in functional muscle recovery
• 89.4% of nerve decompression procedures resulted in complete relief or significant improvement of symptoms

Orthocell Ltd announced latest results from the ongoing Remplir multi-centre post-market clinical follow-up study ('Remplir Real World Evidence study' or 'Remplir RWE Study'). The study demonstrated an overall treatment success rate of 89.7%, based on performance data from 66 patients (78 nerve repair procedures for motor nerve injury or nerve compression). The data will support continued commercial growth across the U.S. and upcoming UK and European markets, with regulatory approval expected in H2 CY26. The cumulative results demonstrate the utility of Remplir across a range of peripheral nerve conditions, including restoration of hand function following cervical spinal cord or brachial plexus injury, and relief of symptoms in chronic nerve injuries such as carpal tunnel syndrome. Results showed that 90.3% of motor nerve repairs achieved functional muscle recovery, and 89.4% of nerve decompression procedures resulted in significant improvement or complete relief of symptoms. No post-treatment complications or adverse effects to Remplir were reported, reinforcing its well-established safety profile and high biocompatibility. The data will play an important role in driving continued commercial growth across the U.S. and upcoming European markets, with regulatory approval expected in H2 CY26.

The data will play an important role in driving continued commercial growth across the U.S. and upcoming European markets, with regulatory approval expected in H2 CY26.